I do not bother much with comparing us to other ASX biotechs as we will be exposed to US investors/ partners and a Nasdaq listing next year, as I see it, and with it to US pricing.
Your comments are correct in regards to other biotechs on the ASX and their reaction to
good news.
Our management was well aware of that and moved corporate business over to the US.
With Haddock and Rosenblatt due for re-election, our corporate side of things are looking promising. They otherwise would have moved on, a company without very enticing outlook in the US market would not be able to hold onto such high calibre BOD members otherwise.
In my humble opinion, Sahm will be replaced by a CEO out of our partner company and
be of a much higher calibre and experience, and probably salary.
The fact that price is now always brought back and parked at 15 cents points to my suggestion 2 or three months ago that I suspected that a MC of just below 500 mil will be our target zone for partner to commit.
It is now the third close in an otherwise choppy trading pattern to close at same price.
We have to be very close indeed Linsanity !
all IMO
PYC Price at posting:
15.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)